Characterizing CLDN18.2 and HER2 expression in gastroesophageal cancer

Tempus RWD reveals CLDN18.2 and HER2 are independent biomarkers in GE cancer

INDICATION
Gastric
BIOMARKER
CLDN18.2

 

Box plot comparing CLDN18.2 expression (RNA-seq) by HER2 IHC levels (Gastric scoring, Ventana 4B5 clone) from matched samples in the Tempus real-world database. CLDN18.2 high defined as the 95% threshold from low-expressing cancers.

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Two pixelated diamond shapes, one purple and one green, with unreadable text below.

Comparing molecular landscapes of early and average onset enteropancreatic NETs

2026-03-06
Gastric
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Multiple low-resolution data plots displaying colored blocks and indistinct text, unreadable.

Outcomes analysis in HER2-low gastric cancer using multimodal RWD

2025-10-09
Gastric
HER2
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract grid of squares showing color gradients and clustered data points.

Shorter Pluvicto treatment course for patients with prostate cancer and high initial PSA

PSA
Prostate